サンプル依頼リスト カート
  • English
  • Korean
表紙：ロザイ・ドルフマン病の世界市場-2023年～2030年
市場調査レポート
商品コード
1345455

ロザイ・ドルフマン病の世界市場-2023年～2030年

Global Rosai-Dorfman Disease Market - 2023-2030
出版日: | 発行: DataM Intelligence | ページ情報: 英文 186 Pages | 納期: 約2営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　 詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=155.11円
ロザイ・ドルフマン病の世界市場-2023年～2030年
出版日: 2023年09月06日
発行: DataM Intelligence
ページ情報: 英文 186 Pages
納期: 約2営業日
ご注意事項 :
本レポートは最新情報反映のため適宜更新し、内容構成変更を行う場合があります。ご検討の際はお問い合わせください。
  • 全表示
  • 概要
  • 目次
概要

概要

ロザイ・ドルフマン病の世界市場は、2022年に4億500万米ドルに達し、2023年から2030年にかけてCAGR 6.6%で成長し、2030年には6億6,750万米ドルに達すると予測されています。

ロザイ・ドルフマン病（RDD）は、組織球と呼ばれる白血球の過剰増殖を伴う稀な良性疾患です。通常、頸部のリンパ腺の腫脹を引き起こしますが、過剰増殖は皮膚や他の臓器に影響を及ぼすこともあります。症状、治療法、予後は個人差があります。

ロザイ・ドルフマン病の患者の多くは小児、10代、若年成人です。RDDの手続き型の平均年齢は20歳前後ですが、70歳代の大人がRDDにかかった例も報告されています。アフリカ系で男性に生まれた人は、リンパ節が侵されるRDDになることが最も多いです。出生時に性別が女性に割り当てられたアジア系の人々は、皮膚RDDと診断されることが最も多いです。CRDD患者の多くは20代、30代、40代です。

RDDは、人によって異なる影響を受けるため、いくつかの理由が考えられます。例えば、現在の調査によると、CRDDは従来のRDDとは異なる病因を持つ可能性が高いです。現在の研究によれば、遺伝子変化を示す節外性RDDはロザイ・ドルフマン病だけではありません。遺伝子変異によって細胞の増殖が制御不能になることもあります。

ダイナミクス

FDA承認の増加

RDDはそのユニークな組織学的特徴と臨床的特徴から、研究者や医療専門家の関心を呼んでいる興味深い疾患です。RDDを理解することは、免疫系とリンパ系が健康と病気の両方においてどのように機能するかを研究者がよりよく理解することにつながります。RDDの臨床試験の数は増加しています。これらの臨床試験は新規治療法の評価に極めて重要であり、そのいずれかが肯定的な結果を出せば、FDAは特定の薬剤や治療法を承認するかもしれません。

例えば、2023年1月30日、エルドハイム・チェスター病、ロザイ・ドルフマン病、ランゲルハンス細胞組織球症などの組織球性新生物の成人患者の治療のために、FDAはコビメチニブ（コテリック）を承認しました。この規制当局の選択は、ジェネンテック社とメモリアル・スローン・ケタリング（MSK）がんセンターとの提携の結果収集された情報に裏付けられたものです。

単施設1群試験のデータによると、コビメチニブは、26人のリクルート患者において、追跡期間中央値11.4カ月でPETによる客観的奏効率（ORR）76.9％、RECIST基準による客観的奏効率（ORR）46.2％を示しました。数年にわたるMSK研究者数名の熱心な研究が、コビメチニブの承認に結実しました。MSKで行われた調査と臨床試験の結果、珍しい悪性腫瘍の分野で大きな進歩が生じています。このように、上記の要因が市場の成長を後押ししています。

ロザイ・ドルフマン病の認知度向上

ロザイ・ドルフマン病に対する認識の高まりにより、ロザイ・ドルフマン病の治療オプションが開発されつつあります。RDDは発見も治療も困難な希少疾患であり、医療専門家も一般住民も、この疾患についてほとんど理解していないことがあります。しかし、RDDに関する情報が入手しやすくなるにつれ、早期診断と適切な治療の重要性に対する理解が高まっています。

患者支援ネットワークや支援団体を通じて、RDDは広く知られるようになってきています。これらのグループは、RDDに対する理解を深め、患者とその家族に情報と支援を提供することを目的としています。このようなグループは、知識や個人的な経験を共有することで、RDDに対する一般の人々や専門家の認識を高めるのに役立っています。

RDDの認知度を高めるもうひとつの重要な方法は、医学会議や教育的取り組みです。このようなイベントでは、学者、医師、企業の幹部が最新の研究結果や治療法を交換することができます。このような機会は、RDDに対する認識と理解を高め、RDD患者の標準治療を向上させるのに役立ちます。このように、上記の要因は市場の成長を加速させるのに役立っています。

ロザイ・ドルフマン病に対する限られた治療選択肢

より広範な疾患と比較すると、RDDは希少疾患であるため、調査対象となる患者の数が少なく、研究に利用できる資源も少ないです。有病率が低いため、大規模な臨床研究を実施し、オーダーメイドの治療法を開発することは困難です。RDDの正確な原因や根本的なメカニズムは完全には解明されていません。重点的な医薬品の開発は、この知識不足によって妨げられています。

RDDでは免疫細胞タイプである組織球が過剰に産生されますが、この過剰産生の原因は不明です。RDDは異質な疾患であり、人によって現れ方が異なります。軽症または自己限定的な人もいれば、より深刻な徴候や問題を抱える人もいます。そのため、RDDの治療選択肢が限られていることが市場拡大の妨げとなります。

目次

第1章 調査手法と調査範囲

第2章 定義と概要

第3章 エグゼクティブサマリー

第4章 市場力学

  • 影響要因
    • 促進要因
      • FDA承認の増加
      • ロザイ・ドルフマン病に対する認知度の向上
    • 抑制要因
      • ロザイ・ドルフマン病に対する限られた治療選択肢
    • 機会
    • 影響分析

第5章 産業分析

  • ポーターのファイブフォース分析
  • サプライチェーン分析
  • 価格分析
  • 規制分析
  • ロシア・ウクライナ戦争の影響分析
  • DMIの見解

第6章 COVID-19分析

第7章 タイプ別

  • 典型的（結節性）ロザイ・ドルフマン病
  • 節外性ロザイ・ドルフマン病

第8章 年齢層別

  • 小児
  • 成人

第9章 手術の種類別

  • 診断
    • 画像診断
      • MRI
      • CTスキャン
      • 核医学検査
    • 血液検査
    • 生検
    • 手術
  • 治療
    • 放射線療法
    • 化学療法
    • 副腎皮質ステロイド
    • 免疫療法

第10章 エンドユーザー別

  • 病院
  • 診断センター
  • がんセンター

第11章 地域別

  • 北米
    • 米国
    • カナダ
    • メキシコ
  • 欧州
    • ドイツ
    • 英国
    • フランス
    • イタリア
    • スペイン
    • その他欧州
  • 南米
    • ブラジル
    • アルゼンチン
    • その他南米
  • アジア太平洋
    • 中国
    • インド
    • 日本
    • オーストラリア
    • その他アジア太平洋
  • 中東・アフリカ

第12章 競合情勢

  • 競合シナリオ
  • 市況/シェア分析
  • M&A分析

第13章 企業プロファイル

  • Koninklijke Philips N.V.
    • 企業概要
    • 製品ポートフォリオと説明
    • 財務概要
    • 主な動向
  • GE HealthCare
  • Canon Inc
  • Siemens Healthineers
  • SternMed GmbH
  • Jubilant Cadista Pharmaceuticals Inc
  • LGM Pharma
  • Henan Lihua Pharmaceutical Co., Ltd
  • Niksan Pharmaceutical
  • Sandoz Canada Inc

第14章 付録

目次
Product Code: PH6811

Overview

Global Rosai-Dorfman Disease Market reached US$ 405.0 million in 2022 and is expected to reach US$ 667.5 million by 2030, growing with a CAGR of 6.6% during the forecast period 2023-2030.

Rosai-Dorfman disease (RDD) is a rare, benign condition that involves an overgrowth of white blood cells called histiocytes. It usually causes swollen lymph glands in the neck, but overgrowths can also affect to skin and other organs. Symptoms, treatment options and likely outcomes vary from person to person.

Most people with Rosai-Dorfman disease are children, teenagers, and young adults. The average age of Procedure Type for RDD is around 20, but incidences of RDD involving adults in their 70s have been documented. People of African origin who are born male most typically get RDD that affects the lymph nodes. People of Asian heritage who are assigned to the female gender at birth are most commonly diagnosed with cutaneous RDD. Most CRDD sufferers are in their 20s, 30s, and 40s.

RDD may have several reasons because each person is affected by it differently. For instance, current research indicates that CRDD is likely to have distinct aetiology from traditional RDD. Rosai-Dorfman disease is not the only extranodal RDD type that occasionally exhibit gene alterations, according to current research. A cell's growth might become uncontrolled due to gene mutations.

Dynamics

The Rise of FDA Approvals

Due to its unique histology and clinical characteristics, RDD is an interesting disease that has sparked the interest of researchers and medical professionals. Understanding RDD can help researchers better understand how the immune and lymphatic systems function in both health and sickness. The number of RDD clinical trials may have increased. These trials are crucial for evaluating novel therapies, and if any of them yield positive findings, the FDA might approve specific drugs or therapies.

For instance, January 30, 2023, For the treatment of adult patients with histiocytic neoplasms like Erdheim-Chester disease, Rosai-Dorfman disease, and Langerhans cell histiocytosis, the FDA has approved cobimetinib (Cotellic). The regulatory choice was supported by information gathered as a result of a partnership between Genentech and Memorial Sloan Kettering (MSK) Cancer Centre.

According to data from the single-center, one-arm trial, cobimetinib produced an objective response rate (ORR) of 76.9% by PET and 46.2% by RECIST criteria in 26 recruited patients at a median follow-up of 11.4 months. The diligent work of several MSK researchers over the course of several years of research culminated in the approval of cobimetinib. As a result of the research and clinical trials carried out at MSK, there have been enormous advancements in the field of uncommon malignancies. Thus above factors helps to boost the market growth.

Raising Awareness of Rosai-Dorfman Disease

Rosai-Dorfman Disease treatment options are being developed as a result of rising Rosai-Dorfman Disease awareness. RDD is a rare disease that can be difficult to detect and treat, and both healthcare professionals and the general population sometimes have little understanding of the condition. However, there is rising understanding of the significance of early diagnosis and proper treatment as more information regarding RDD becomes accessible.

Through patient support networks and advocacy groups, RDD is becoming more widely known. These groups look for to increase understanding of RDD and offer information and support to patients and their families. These groups aid in raising public and professional awareness of RDD by sharing knowledge and personal experiences.

An additional significant method for raising awareness of RDD is through medical conferences and educational initiatives. These events give scholars, doctors, and executives from businesses the chance to exchange the most recent research findings and treatments. These occasions assist to raise awareness and understanding of RDD, which enhances the standard of care for patients with RDD. Thus above factors helps to accelerate the market growth.

Limited Treatment Options for the Rosai-Dorfman Disease

Compared to more widespread disorders, RDD is a rare disease, thus there are fewer patients to study and fewer resources available for research. It is difficult to conduct extensive clinical studies and create tailored treatments because of the low prevalence. RDD's precise cause and underlying mechanisms are not completely understood. The development of focused medicines is hampered by this lack of knowledge.

Histiocytes, an immunological cell type, are produced excessively in RDD, however it is unclear what causes this excessive production. RDD is a heterogeneous condition, which means that it can manifest differently in various people. While some people have mild or self-limiting illnesses, others might have more serious signs or problems. Thus, the market's expansion will be hindered by the limited treatment options for the RDD.

Segment Analysis

The global rosai-dorfman disease market is segmented based on type, age group, procedure type, end user and region.

Chemotherapy Play a Critical Part in the Treatment of RDD

Chemotherapy is not typically the first-line treatment for rosai-dorfman disease. RDD is a rare disorder characterized by the overproduction and accumulation of histiocytes (a type of immune cell) in lymph nodes and other tissues. The choice of treatment for RDD depends on the severity of the disease, its location, and the symptoms it causes.

The primary treatment for RDD usually involves a watch-and-wait approach, especially for cases where the disease is mild and not causing significant symptoms or organ dysfunction. In such cases, spontaneous regression or no progression of the disease is common, and treatment may not be necessary. However, if RDD is causing severe symptoms, such as organ dysfunction, pain, or compression of vital structures, treatment may be required.

Additionally, chemotherapy may be considered in cases of RDD with widespread or systemic involvement, particularly when other treatments have failed or when rapid progression is observed. Various chemotherapy regimens have been used, including corticosteroids, vinca alkaloids, and immune-modulating agents.

Geographical Penetration

Rising Clinical Trails and Product Launches in the North American Region

North America dominates the global rosai-dorfman disease market primarily due to its large population, excellent medical infrastructure, and high-income levels. The global rosai-dorfman disease is based on a number of micro- and macroeconomic variables. The prevalence of diseases associated with blood like cancer and viral infections contributes to the market's expansion.

Increased need for faster diagnosis led companies in the region to concentrate on more sophisticated methods. It is expected that an increase in clinical trials that have not yet received approval will accelerate market expansion. It is anticipated that the drug manufacturers will benefit as more individuals sign up for clinical trials as a result of increased consumer knowledge of blood-related diseases among consumers brought on by doctors, patients, advocacy groups, and researchers.

Throughout the projected period, the Asia Pacific is expected to witness fastest growth. Government programmes aimed at helping people with orphan diseases are to blame for the region's expansion.

COVID-19 Impact Analysis

Healthcare systems in numerous regions noticed serious difficulties during the COVID-19 epidemic, including resource shortages and disruptions in regular medical treatment. Access to healthcare services, including monitoring and treatment of RDD patients' conditions, may have been impacted by this. Clinical trials and research have been hampered by the epidemic in many different medical specialties. The pandemic may have slowed down or damaged RDD research, which could have slowed down the understanding and treatment of the condition.

By Type

  • Classic (nodal) Rosai-Dorfman disease
  • Extranodal Rosai-Dorfman disease

By Age Group

  • Children
  • Adults

By Procedure Type

  • Diagnosis
    • Imaging procedures
      • MRI
      • CT scan
      • Nuclear medicine
  • Blood tests
  • Biopsy
    • Treatment
      • Surgery
      • Radiation therapy
      • Chemotherapy
      • Corticosteroids
      • Immunotherapy

By End User

  • Hospitals
  • Diagnostic centers
  • Cancer centers

By Region

  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • Germany
    • UK
    • France
    • Italy
    • Spain
    • Rest of Europe
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia-Pacific
    • China
    • India
    • Japan
    • Australia
    • Rest of Asia-Pacific
  • Middle East and Africa

Key Developments

  • On November 28, 2022, at a city private hospital, a patient with Rosai-Dorfman disease (RDD), a rare immunological condition that had compromised his heart, was effectively treated. Only eight cases of the illness that affects the eyes and the heart have been reported so far in the entire world.

Competitive Landscape

The major global players in the market include: Koninklijke Philips N.V., GE HealthCare, Canon Inc, Siemens Healthineers, SternMed GmbH, Jubilant Cadista Pharmaceuticals Inc, LGM Pharma, Henan Lihua Pharmaceutical Co., Ltd, Niksan Pharmaceutical, Sandoz Canada Inc and among others.

Why Purchase the Report?

  • To visualize the global rosai-dorfman disease market segmentation based on type, age group, procedure type, end user and region as well as understandkey commercial assets and players.
  • Identify commercial opportunities by analyzing trends and co-development.
  • Excel data sheet with numerous data points of rosai-dorfman disease market-level with all segments.
  • PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
  • Product mapping available as excel consisting of key products of all the major players.

The global Rosai-Dorfman Disease market report would provide approximately 61tables, 58figures and 186 Pages.

Target Audience 2023

  • Manufacturers/ Buyers
  • Industry Investors/Investment Bankers
  • Research Professionals
  • Emerging Companies

Table of Contents

1. Methodology and Scope

  • 1.1. Research Methodology
  • 1.2. Research Objective and Scope of the Report

2. Definition and Overview

3. Executive Summary

  • 3.1. Snippet by Type
  • 3.2. Snippet by Age Group
  • 3.3. Snippet by Procedure Type
  • 3.4. Snippet by End User
  • 3.5. Snippet by Region

4. Dynamics

  • 4.1. Impacting Factors
    • 4.1.1. Drivers
      • 4.1.1.1. The rise of FDA Approvals
      • 4.1.1.2. Raising awareness of Rosai-Dorfman Disease
  • 4.2. Restraints
      • 4.2.1.1. Limited Treatment Options for the Rosai-Dorfman Disease
    • 4.2.2. Opportunity
    • 4.2.3. Impact Analysis

5. Industry Analysis

  • 5.1. Porter's Five Force Analysis
  • 5.2. Supply Chain Analysis
  • 5.3. Pricing Analysis
  • 5.4. Regulatory Analysis
  • 5.5. Russia-Ukraine War Impact Analysis
  • 5.6. DMI Opinion

6. COVID-19 Analysis

  • 6.1. Analysis of COVID-19
    • 6.1.1. Scenario Before COVID
    • 6.1.2. Scenario During COVID
    • 6.1.3. Scenario Post COVID
  • 6.2. Pricing Dynamics Amid COVID-19
  • 6.3. Demand-Supply Spectrum
  • 6.4. Government Initiatives Related to the Market During Pandemic
  • 6.5. Manufacturers Strategic Initiatives
  • 6.6. Conclusion

7. By Type

  • 7.1. Introduction
    • 7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
    • 7.1.2. Market Attractiveness Index, By Type
  • 7.2. Classic (nodal) Rosai-Dorfman disease*
    • 7.2.1. Introduction
    • 7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 7.3. Extranodal Rosai-Dorfman disease

8. By Age Group

  • 8.1. Introduction
    • 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), ByAge Group
    • 8.1.2. Market Attractiveness Index, By Age Group
  • 8.2. Children*
    • 8.2.1. Introduction
    • 8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 8.3. Adults

9. By Procedure Type

  • 9.1. Introduction
    • 9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Procedure Type
    • 9.1.2. Market Attractiveness Index, By Procedure Type
  • 9.2. *Diagnosis
    • 9.2.1. Introduction
    • 9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
    • 9.2.3. Imaging procedures
      • 9.2.3.1. MRI
      • 9.2.3.2. CT scan
      • 9.2.3.3. Nuclear medicine
    • 9.2.4. Blood tests
    • 9.2.5. Biopsy
    • 9.2.6. Surgery
  • 9.3. Treatment
    • 9.3.1. Radiation therapy
    • 9.3.2. Chemotherapy
    • 9.3.3. Corticosteroids
    • 9.3.4. Immunotherapy

10. By End User

  • 10.1. Introduction
    • 10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
    • 10.1.2. Market Attractiveness Index, By End User
  • 10.2. Hospitals*
    • 10.2.1. Introduction
    • 10.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 10.3. Diagnostic centers
  • 10.4. Cancer centers

11. By Region

  • 11.1. Introduction
    • 11.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
    • 11.1.2. Market Attractiveness Index, By Region
  • 11.2. North America
    • 11.2.1. Introduction
    • 11.2.2. Key Region-Specific Dynamics
    • 11.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
    • 11.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Age Group
    • 11.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Procedure Type
    • 11.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
    • 11.2.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 11.2.7.1. U.S.
      • 11.2.7.2. Canada
      • 11.2.7.3. Mexico
  • 11.3. Europe
    • 11.3.1. Introduction
    • 11.3.2. Key Region-Specific Dynamics
    • 11.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
    • 11.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Age Group
    • 11.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Procedure Type
    • 11.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
    • 11.3.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 11.3.7.1. Germany
      • 11.3.7.2. UK
      • 11.3.7.3. France
      • 11.3.7.4. Italy
      • 11.3.7.5. Spain
      • 11.3.7.6. Rest of Europe
  • 11.4. South America
    • 11.4.1. Introduction
    • 11.4.2. Key Region-Specific Dynamics
    • 11.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
    • 11.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Age Group
    • 11.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Procedure Type
    • 11.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
    • 11.4.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 11.4.7.1. Brazil
      • 11.4.7.2. Argentina
      • 11.4.7.3. Rest of South America
  • 11.5. Asia-Pacific
    • 11.5.1. Introduction
    • 11.5.2. Key Region-Specific Dynamics
    • 11.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
    • 11.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Age Group
    • 11.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Procedure Type
    • 11.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
    • 11.5.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 11.5.7.1. China
      • 11.5.7.2. India
      • 11.5.7.3. Japan
      • 11.5.7.4. Australia
      • 11.5.7.5. Rest of Asia-Pacific
  • 11.6. Middle East and Africa
    • 11.6.1. Introduction
    • 11.6.2. Key Region-Specific Dynamics
    • 11.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
    • 11.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Age Group
    • 11.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Procedure Type
    • 11.6.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User

12. Competitive Landscape

  • 12.1. Competitive Scenario
  • 12.2. Market Positioning/Share Analysis
  • 12.3. Mergers and Acquisitions Analysis

13. Company Profiles

  • 13.1. Koninklijke Philips N.V.*
    • 13.1.1. Company Overview
    • 13.1.2. Product Portfolio and Description
    • 13.1.3. Financial Overview
    • 13.1.4. Key Developments
  • 13.2. GE HealthCare
  • 13.3. Canon Inc
  • 13.4. Siemens Healthineers
  • 13.5. SternMed GmbH
  • 13.6. Jubilant Cadista Pharmaceuticals Inc
  • 13.7. LGM Pharma
  • 13.8. Henan Lihua Pharmaceutical Co., Ltd
  • 13.9. Niksan Pharmaceutical
  • 13.10. Sandoz Canada Inc

LIST NOT EXHAUSTIVE

14. Appendix

  • 14.1. About Us and Services
  • 14.2. Contact Us